Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer
Conditions
Brief summary
This randomized phase II trial is studying the side effects and how well giving oxaliplatin or mitomycin C directly into the abdomen after surgery works in treating patients with tumors of the appendix. Drugs used in chemotherapy, such as oxaliplatin and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
Detailed description
PRIMARY OBJECTIVES: I. To compare the toxicity profiles within 4 weeks of surgery of oxaliplatin and mitomycin C delivered via Hyperthermic Intraperitoneal Chemotherapy in patients with peritoneal surface malignancies from primary appendiceal tumors. SECONDARY OBJECTIVES: I. To compare the time to progression in patients treated with oxaliplatin vs. mitomycin C delivered via Hyperthermic Intraperitoneal Chemotherapy for surface malignancies from primary appendiceal tumors. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients undergo surgical cytoreduction and receive mitomycin C by hyperthermic intraperitoneal chemotherapy (HIPEC). Arm II: Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC. After completion of study treatment, patients are followed up at 6, 12, 18, 24, 30, and 36 months.
Interventions
DRUGmitomycin C
Given by HIPEC
DRUGoxaliplatin
Given by HIPEC
PROCEDUREtherapeutic conventional surgery
Undergo surgery
OTHERquality-of-life assessment
Ancillary studies
DRUGhyperthermic intraperitoneal chemotherapy
Undergo HIPEC
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumors * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Absolute neutrophil count \>= 1,500/mcL * Platelets \>=100,000/mcL * Total bilirubin =\< 1.5 mg/dL * Creatinine =\< 2.0 mg/dL * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 3 X institutional upper limit of normal * Alkaline phosphatase =\< 3 X institutional upper limit of normal * Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or double-barrier method of birth control; abstinence) for the duration of study participation and for 90 days following HIPEC * Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative) * Participants who have received oxaliplatin during prior systemic chemotherapy regimens are eligible for enrollment in this protocol
Exclusion criteria
* Patients with an active infection or with a fever \>= 101.3 degrees Fahrenheit (F) within 3 days of the first scheduled day of protocol treatment * Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication) * Patients with carcinoid tumors * Patients with active central nervous system (CNS) metastases * Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C * History of prior malignancy within the past 5 years, except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate-specific antigen (PSA) of \< 1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry * Patients who received radiotherapy to more than 25% of their bone marrow * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant/nursing women are excluded from this study because oxaliplatin is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with oxaliplatin, breastfeeding should be discontinued if the mother is treated with oxaliplatin or mitomycin C * Known human immunodeficiency virus (HIV), hepatitis B or C-positive patients (active, previously treated or both) * Peripheral neuropathy \>= grade 2 * History of allogenic transplant * History of prior HIPEC * Evidence of metastatic disease outside of the abdomen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments | Within 4 weeks of surgery | If a patient has a grade 3 or 4 standard hematologic toxicity (leukopenia, thrombocytopenia, and neutropenia), the patient will be considered to be an event. The observed rates of the 2 treatments will be the primary outcome, and the rates will be analyzed using a 2-sided chi-square test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years | Time to first progression unless the patient's resection status is R2b or 2c, regardless of toxicity or response to study drug, assessed up to 3 years | — |
| The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years | Interval between surgery and death or date of last contact, assessed up to 3 years | — |
| Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G) | Throughout study completion, up to 3 years | The FACT-G (Functional Assessment of Cancer Therapy - General) consists of 27 core items assessing patient well-being in four components: Physical (7 items), Social/Family (7 items), Emotional (6 items), and Functional (7 items). Items are rated on a five-point scale: 0-not at all, 1- a little bit, 2-somewhat, 3- quite a bit and 4-very much. The score of each component is the mean times the number of items in the component. The range of the physical, social/family, and functional components I 0-28 and the range of the emotional component is 0-24. The sum of the component scores creates the overall score which has a range of 0-108. For all component scores and overall score, the higher the score the better the QOL. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Mitomycin C) Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
mitomycin C: Given by HIPEC
therapeutic conventional surgery: Undergo surgery
quality-of-life assessment: Ancillary studies
hyperthermic intraperitoneal chemotherapy: Undergo HIPEC | 68 |
| Arm II (Oxaliplatin) Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
oxaliplatin: Given by HIPEC
therapeutic conventional surgery: Undergo surgery
quality-of-life assessment: Ancillary studies
hyperthermic intraperitoneal chemotherapy: Undergo HIPEC | 68 |
| Total | 136 |
Baseline characteristics
| Characteristic | Arm I (Mitomycin C) | Arm II (Oxaliplatin) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 22 Participants | 20 Participants | 42 Participants |
| Age, Categorical Between 18 and 65 years | 46 Participants | 48 Participants | 94 Participants |
| Age, Continuous | 55.9 years STANDARD_DEVIATION 12.9 | 55.0 years STANDARD_DEVIATION 14 | 55.5 years STANDARD_DEVIATION 13.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 3 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 64 Participants | 65 Participants | 129 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 5 Participants | 9 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 63 Participants | 62 Participants | 125 Participants |
| Region of Enrollment United States | 68 participants | 68 participants | 136 participants |
| Sex: Female, Male Female | 35 Participants | 40 Participants | 75 Participants |
| Sex: Female, Male Male | 33 Participants | 28 Participants | 61 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 58 | 1 / 61 |
| other Total, other adverse events | 58 / 58 | 61 / 61 |
| serious Total, serious adverse events | 51 / 58 | 54 / 61 |
Outcome results
Primary
The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments
If a patient has a grade 3 or 4 standard hematologic toxicity (leukopenia, thrombocytopenia, and neutropenia), the patient will be considered to be an event. The observed rates of the 2 treatments will be the primary outcome, and the rates will be analyzed using a 2-sided chi-square test.
Time frame: Within 4 weeks of surgery
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Mitomycin C) | The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments | 8 number of patients with toxicities |
| Arm II (Oxaliplatin) | The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments | 5 number of patients with toxicities |
Secondary
Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G)
The FACT-G (Functional Assessment of Cancer Therapy - General) consists of 27 core items assessing patient well-being in four components: Physical (7 items), Social/Family (7 items), Emotional (6 items), and Functional (7 items). Items are rated on a five-point scale: 0-not at all, 1- a little bit, 2-somewhat, 3- quite a bit and 4-very much. The score of each component is the mean times the number of items in the component. The range of the physical, social/family, and functional components I 0-28 and the range of the emotional component is 0-24. The sum of the component scores creates the overall score which has a range of 0-108. For all component scores and overall score, the higher the score the better the QOL.
Time frame: Throughout study completion, up to 3 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Mitomycin C) | Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G) | 85.5 units on a scale | Standard Error 1.6 |
| Arm II (Oxaliplatin) | Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G) | 89.6 units on a scale | Standard Error 1.7 |
Secondary
The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years
Time frame: Time to first progression unless the patient's resection status is R2b or 2c, regardless of toxicity or response to study drug, assessed up to 3 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Mitomycin C) | The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years | 61.6 disease-free survival rate (%) | Standard Error 8.1 |
| Arm II (Oxaliplatin) | The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years | 59.4 disease-free survival rate (%) | Standard Error 8.1 |
Secondary
The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years
Time frame: Interval between surgery and death or date of last contact, assessed up to 3 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Mitomycin C) | The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years | 75.7 overall survival rate (%) | Standard Error 6.4 |
| Arm II (Oxaliplatin) | The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years | 79.3 overall survival rate (%) | Standard Error 5.7 |